Chinese Drug Maker Recalls All Injectable Products After TCM Case
This article was originally published in PharmAsia News
China's Wandashan Pharmaceutical expanded its recall of a contaminated TCM injection to include all of its injectable products. Chinese agencies said the company acted voluntarily to expand the recall. Local and national investigators looking into three deaths attributed to the Siberian ginseng injections, ciwujia, determined the injections were contaminated with bacteria, but have not determined how. State FDA regulations require drug makers to investigate and evaluate drugs that might have hidden safety problems, and recall them if they do. (Click here for more
You may also be interested in...
This month’s column covers deals announced between 1-23 April 2020.
Celltrion’s Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the WHO.
EU MDR Panel Discussion: Why An Extra Year Is Not Really A Delay For The MDR – How To Survive Changing And Confusing Times
26 May 2020, the date that the Medical Device Regulation was originally due to apply in the EU, was a good time to take stock of where the medtech sector finds itself. Three of the most renowned and outspoken experts on the EU medical device regulatory system gave their views in this exclusive interview.